Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK MRNA
Merck Announces Fourth-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive European Union CHMP Opinion for Gefapixant
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Completes Acquisition of Prometheus Biosciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in Bank of America Securities 2023 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK RXDX
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.